204 related articles for article (PubMed ID: 19375669)
1. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
Paillard F
Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
[No Abstract] [Full Text] [Related]
2. Drugs for hypertriglyceridemia.
Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
[No Abstract] [Full Text] [Related]
3. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
Ferrières J; Bérard E; Crisan O; Bongard V
Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
[TBL] [Abstract][Full Text] [Related]
4. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
Shah PK
Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
[TBL] [Abstract][Full Text] [Related]
5. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
6. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
7. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
10. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
Nicholls SJ; Lundman P; Tardif JC
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
[TBL] [Abstract][Full Text] [Related]
11. [Update: clinical lipidology].
Parhofer KG
MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
[No Abstract] [Full Text] [Related]
12. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL
J Am Coll Cardiol; 2008 Apr; 51(15):1512-24. PubMed ID: 18402913
[No Abstract] [Full Text] [Related]
13. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
14. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
[TBL] [Abstract][Full Text] [Related]
15. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
Capriotti T
Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
[No Abstract] [Full Text] [Related]
16. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
17. [Hypertricglyceridemia: prognostic impact and treatment options].
Custodis F; Laufs U
Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752
[TBL] [Abstract][Full Text] [Related]
18. Keeping our eyes on the prize: low density lipoprotein cholesterol.
de Lemos JA; Khera A
Am J Cardiol; 2009 Dec; 104(12):1697-8. PubMed ID: 19962478
[No Abstract] [Full Text] [Related]
19. Fenofibrates get a second look. Research shows popular drugs fail to lower cardiovascular risk for most patients already taking a statin.
Heart Advis; 2010 Jun; 13(6):4-5. PubMed ID: 23166970
[No Abstract] [Full Text] [Related]
20. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
